HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC

A Study of RC48-ADC in Subjects With Advanced Breast Cancer

NCT03052634 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2

De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients

NCT06700369 ·Status: RECRUITING

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

NCT05824325 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

NCT05810103 ·Status: UNKNOWN ·Phase: PHASE1

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

NCT03927456 ·Status: UNKNOWN ·Phase: PHASE3

A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

NCT05331326 ·Status: UNKNOWN ·Phase: PHASE2

Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients

NCT05839288 ·Status: COMPLETED

Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer

NCT06492447 ·Status: NOT_YET_RECRUITING

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

NCT05769751 ·Status: COMPLETED

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

NCT05263570 ·Status: RECRUITING

B002 in Patients With HER2-positive Breast Cancer

NCT04382352 ·Status: COMPLETED ·Phase: PHASE1

Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

NCT05295043 ·Status: UNKNOWN ·Phase: NA

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

NCT06343948 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

NCT07005557 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression

NCT07047443 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

NCT04681287 ·Status: UNKNOWN ·Phase: PHASE2

Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors

NCT04146610 ·Status: UNKNOWN ·Phase: PHASE1

Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer

NCT05334147 ·Status: UNKNOWN

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

NCT05525767 ·Status: RECRUITING ·Phase: PHASE4

Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer

NCT07162259 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

NCT05981014 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT06927180 ·Status: RECRUITING ·Phase: PHASE2

Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

NCT07305246 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

NCT07023861 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1